» Articles » PMID: 39376607

FGF21 Inhibits Ferroptosis Caused by Mitochondrial Damage to Promote the Repair of Peripheral Nerve Injury

Overview
Journal Front Pharmacol
Date 2024 Oct 8
PMID 39376607
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Ferroptosis is a new type of cell death characterized by lipid peroxidation and iron dependency, representing an emerging disease regulation mechanism. The limited understanding of ferroptosis in peripheral nerve injury (PNI) complicates the management of such injuries. Mitochondrial dysfunction, which contributes to ferroptosis, further exacerbates the challenges of peripheral nerve repair.

Methods: In this study, we established an in vitro model of Schwann cells model treated with TBHP and an in vivo sciatic nerve crush injury model in rats. These models were used to investigate the effects of fibroblast growth factor 21 (FGF21) on PNI, both in vitro and in vivo, and to explore the potential mechanisms linking injury-induced ferroptosis and mitochondrial dysfunction.

Results: Our findings reveal that PNI triggers abnormal accumulation of lipid reactive oxygen species (ROS) and inactivates mitochondrial respiratory chain complex III, leading to mitochondrial dysfunction. This dysfunction catalyzes the oxidation of excessive polyunsaturated fatty acids, resulting in antioxidant imbalance and loss of ferroptosis suppressor protein 1 (FSP1), which drives lipid peroxidation. Additionally, irregular iron metabolism, defective mitophagy, and other factors contribute to the induction of ferroptosis. Importantly, we found that FGF21 attenuates the abnormal accumulation of lipid ROS, restores mitochondrial function, and suppresses ferroptosis, thus promoting PNI repair. Notably, glutathione peroxidase 4 (GPX4), a downstream target of nuclear factor E2-related factor 2 (Nrf2), and the ERK/Nrf2 pathway are involved in the regulation of ferroptosis by FGF21.

Conclusion: FGF21 promotes peripheral nerve repair by inhibiting ferroptosis caused by mitochondrial dysfunction. Therefore, targeting mitochondria and ferroptosis represents a promising therapeutic strategy for effective PNI repair.

Citing Articles

Fibroblast Growth Factor 21 Protects Against Cerebral Ischemia/Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis.

Li J, Jiang H, Bai W, Yang Y, Zhou G, Chen W Neuropsychiatr Dis Treat. 2025; 21:355-371.

PMID: 40027603 PMC: 11871945. DOI: 10.2147/NDT.S504180.


Aerobic Exercise Activates Fibroblast Growth Factor 21 and Alleviates Cardiac Ischemia/Reperfusion-induced Neuronal Oxidative Stress and Ferroptosis in Paraventricular Nucleus.

Zhao Y, Feng L, Wu C, Xu Y, Bo W, Di L Mol Neurobiol. 2025; .

PMID: 40009261 DOI: 10.1007/s12035-025-04780-1.


Autophagy in Tissue Repair and Regeneration.

Moreno-Blas D, Adell T, Gonzalez-Estevez C Cells. 2025; 14(4).

PMID: 39996754 PMC: 11853389. DOI: 10.3390/cells14040282.

References
1.
Beirowski B, Adalbert R, Wagner D, Grumme D, Addicks K, Ribchester R . The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci. 2005; 6:6. PMC: 549193. DOI: 10.1186/1471-2202-6-6. View

2.
Gomez-Samano M, Grajales-Gomez M, Zuarth-Vazquez J, Navarro-Flores M, Martinez-Saavedra M, Juarez-Leon O . Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017; 11:335-341. PMC: 5200873. DOI: 10.1016/j.redox.2016.12.024. View

3.
Koppula P, Lei G, Zhang Y, Yan Y, Mao C, Kondiparthi L . A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun. 2022; 13(1):2206. PMC: 9033817. DOI: 10.1038/s41467-022-29905-1. View

4.
Doll S, Porto Freitas F, Shah R, Aldrovandi M, Costa Da Silva M, Ingold I . FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019; 575(7784):693-698. DOI: 10.1038/s41586-019-1707-0. View

5.
Huang L, Bian M, Zhang J, Jiang L . Iron Metabolism and Ferroptosis in Peripheral Nerve Injury. Oxid Med Cell Longev. 2022; 2022:5918218. PMC: 9733998. DOI: 10.1155/2022/5918218. View